The Forum member who relapsed twice on S/L was username 'HR'. Cheers.
Isiscat2011 said
Oct 12, 2014
mallani wrote:
They are very similar, with the same activity numbers and resistance profiles.
As Gilead are not marketing Ledipasvir separately, the cost of Sovaldi + Daclatasvir will not be competitive. BMS are flogging a dead horse with Daklinza (Daclatasvir).
Oh, Man. That does make sense because even if Sovaldi could be purchased separately Daclatasvir would have to be priced very low to compete with Harvoni. I keep hoping that somebody is going to give Gilead a run for their money just to drive the costs down. Maybe Abbvie will do it but I'm kind of stuck on favoring Sovaldi as the backbone and would like to see more people getting it.
mallani said
Oct 12, 2014
They are very similar, with the same activity numbers and resistance profiles.
As Gilead are not marketing Ledipasvir separately, the cost of Sovaldi + Daclatasvir will not be competitive. BMS are flogging a dead horse with Daklinza (Daclatasvir).
Isiscat2011 said
Oct 12, 2014
Malcolm:
Is it safe to assume that since Ledipasvir and Declatasvir are both NS5A inhibitors they are very similar with respect to efficacy and safety/side effects? How do they differ?
Isiscat2011 said
Oct 12, 2014
Thanks, Malcolm. Excellent tip in figuring out the drug class by the name.
The person I was thinking of did 12 weeks on S/L, relapsed, and then repeated S/L for 24 weeks and relapsed again. I was very surprised. He doesn't post often and his sn escapes me. Matt would probably remember because I think he has been following the S/L patients closely too.
mallani said
Oct 12, 2014
Sorry Isis,
Daclatasvir is a NS5A inhibitor, same as Ledipasvir. (all drugs ending in ...asvir are NS5A inhibitors, and all ending in .........previr are protease inhibitors).
In another thread, I think you were referring to Rockyfeller (Jim). He did 12 weeks of Sovaldi/ Peg/ Riba in July 2012. He relapsed 4 weeks after EOT.
He then did 12 weeks of Sovaldi/ Ledipasvir/Riba in Dec 2013. He has achieved SVR.
So, in his case, retreatment with Sovaldi was successful. Cheers.
skewedButNotBroken said
Oct 12, 2014
Very informing---thanks!
Isiscat2011 said
Oct 12, 2014
Very interesting, but it still doesn't answer the hard questions. His treatment strategies do not include Harvoni or Abbive or any future combos specifically so they are of limited value. He recommends Sovaldi/Declatasvir for retreatment of those who have failed tx, where Sovaldi was the ONLY DAA used, which is your situation. This is probably because he is a European researcher and Declatasvir is potentially available in Europe but not yet in the US.
Declatasvir is not in the same drug class as Ledipasvir. Declatasvir is a PI while Ledipasvir is an NS5A inhibitor. Don't know what impact that distinction would have but it is all theoretical at this stage.
The best source for information regarding Sovaldi and Ledipasvir is Gilead and they aren't answering these questions.
Hi Isis,
The Forum member who relapsed twice on S/L was username 'HR'. Cheers.
Oh, Man. That does make sense because even if Sovaldi could be purchased separately Daclatasvir would have to be priced very low to compete with Harvoni. I keep hoping that somebody is going to give Gilead a run for their money just to drive the costs down. Maybe Abbvie will do it but I'm kind of stuck on favoring Sovaldi as the backbone and would like to see more people getting it.
They are very similar, with the same activity numbers and resistance profiles.
As Gilead are not marketing Ledipasvir separately, the cost of Sovaldi + Daclatasvir will not be competitive. BMS are flogging a dead horse with Daklinza (Daclatasvir).
Malcolm:
Is it safe to assume that since Ledipasvir and Declatasvir are both NS5A inhibitors they are very similar with respect to efficacy and safety/side effects? How do they differ?
Thanks, Malcolm. Excellent tip in figuring out the drug class by the name.
The person I was thinking of did 12 weeks on S/L, relapsed, and then repeated S/L for 24 weeks and relapsed again. I was very surprised. He doesn't post often and his sn escapes me. Matt would probably remember because I think he has been following the S/L patients closely too.
Sorry Isis,
Daclatasvir is a NS5A inhibitor, same as Ledipasvir. (all drugs ending in ...asvir are NS5A inhibitors, and all ending in .........previr are protease inhibitors).
In another thread, I think you were referring to Rockyfeller (Jim). He did 12 weeks of Sovaldi/ Peg/ Riba in July 2012. He relapsed 4 weeks after EOT.
He then did 12 weeks of Sovaldi/ Ledipasvir/Riba in Dec 2013. He has achieved SVR.
So, in his case, retreatment with Sovaldi was successful. Cheers.
Very informing---thanks!
Very interesting, but it still doesn't answer the hard questions. His treatment strategies do not include Harvoni or Abbive or any future combos specifically so they are of limited value. He recommends Sovaldi/Declatasvir for retreatment of those who have failed tx, where Sovaldi was the ONLY DAA used, which is your situation. This is probably because he is a European researcher and Declatasvir is potentially available in Europe but not yet in the US.
Declatasvir is not in the same drug class as Ledipasvir. Declatasvir is a PI while Ledipasvir is an NS5A inhibitor. Don't know what impact that distinction would have but it is all theoretical at this stage.
The best source for information regarding Sovaldi and Ledipasvir is Gilead and they aren't answering these questions.
Good news
http://www.informedhorizons.com/resistance2014/pdf/Presentations/Pawlotsky_MAC_BERLIN-RESISTANCE.pdf